M ore than 3.5 million skin cancers are diagnosed every year in the United States. 1Y3 The most common types of skin cancer are basal cell carcinoma and squamous cell carcinoma, which are responsible for approximately 2.8 million and 700,000 annual cases, respectively. Melanoma, the third most common type of skin cancer, will be diagnosed in an estimated 76,250 patients in the United States in 2012. While melanoma represents less than 5% of skin cancer diagnoses, it is the cause of more than 75% of the deaths attributable to skin cancer each year. In addition to its highly aggressive nature, the clinical significance of melanoma is underscored by the fact that the patients who die from this disease are often otherwise young and healthy. Melanoma is second only to testicular cancer among adult malignancies in the average life-years lost per fatality, and the estimated annual economic cost of melanoma from lost productivity is $3.5 billion. 4 Further, both the incidence and annual mortality of melanoma have increased dramatically during the last few decades. 5 Thus, there is a critical need to improve the understanding, prevention, and treatment of this disease.
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